Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$23.53
+0.5%
$23.82
$12.42
$31.77
$2.95B1.581.31 million shs123,165 shs
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$76.86
+2.6%
$63.70
$12.44
$77.90
$10.76B1.282.61 million shs178,710 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$226.15
+1.4%
$171.73
$96.09
$234.29
$11.63B0.59699,952 shs120,939 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.96
+8.6%
$23.82
$10.75
$27.72
$12.28B1.694.87 million shs2.84 million shs
10 Best Stocks to Own in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
+0.30%+0.56%-0.89%-10.20%+51.98%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+0.16%+6.81%+22.78%+10.09%+435.98%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+8.00%+20.57%+32.37%+20.22%+91.48%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+2.25%+3.83%-0.26%-5.69%+139.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$23.53
+0.5%
$23.82
$12.42
$31.77
$2.95B1.581.31 million shs123,165 shs
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$76.86
+2.6%
$63.70
$12.44
$77.90
$10.76B1.282.61 million shs178,710 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$226.15
+1.4%
$171.73
$96.09
$234.29
$11.63B0.59699,952 shs120,939 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$24.96
+8.6%
$23.82
$10.75
$27.72
$12.28B1.694.87 million shs2.84 million shs
10 Best Stocks to Own in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
+0.30%+0.56%-0.89%-10.20%+51.98%
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
+0.16%+6.81%+22.78%+10.09%+435.98%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+8.00%+20.57%+32.37%+20.22%+91.48%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+2.25%+3.83%-0.26%-5.69%+139.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
2.50
Moderate Buy$34.0044.49% Upside
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
2.83
Moderate Buy$84.209.55% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.90
Moderate Buy$251.2611.10% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$27.9011.77% Upside

Current Analyst Ratings Breakdown

Latest ARQT, ELAN, ARWR, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Set Price Target$280.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$225.00 ➝ $255.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$242.00 ➝ $302.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$270.00 ➝ $290.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetEqual Weight$217.00 ➝ $242.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOverweight$225.00 ➝ $255.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$228.00 ➝ $310.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$241.00 ➝ $246.00
5/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Set Price Target$280.00
5/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$245.00 ➝ $260.00
5/1/2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
Initiated CoverageOverweight$88.00
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$376.07M7.83N/AN/A$1.55 per share15.18
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
$829.45M12.98$0.12 per share639.78$3.64 per share21.12
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M18.22N/AN/A$1.75 per share129.23
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.63$2.57 per share9.70$13.18 per share1.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$16.14M-$0.14N/A23.07N/A-4.29%-10.26%-4.30%5/6/2026 (Estimated)
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.63M$1.5350.23N/AN/A18.54%35.64%13.61%5/7/2026 (Estimated)
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.69N/A40.53N/A-26.59%-246.90%-29.04%N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.48N/A21.342.87-4.92%7.16%3.53%5/6/2026 (Estimated)

Latest ARQT, ELAN, ARWR, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q2 2026
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
-$1.1068N/AN/AN/A$73.84 millionN/A
5/6/2026Q1 2026
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
-$0.02N/AN/AN/A$103.68 millionN/A
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
2/25/2026Q4 2025
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
$0.03$0.13+$0.10$999.00$110.79 million$129.50 million
2/24/2026Q4 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.11$0.13+$0.02-$0.56$1.09 billion$1.14 billion
2/23/2026Q4 2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.70-$0.56+$0.14-$0.56$191.33 million$196.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
N/AN/AN/AN/AN/A
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
0.57
3.17
2.99
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
0.29
3.38
3.38
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1.38
1.55
1.48
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.17
1.08
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcutis Biotherapeutics, Inc. stock logo
ARQT
Arcutis Biotherapeutics
150125.07 million113.32 millionOptionable
Arrowhead Pharmaceuticals, Inc. stock logo
ARWR
Arrowhead Pharmaceuticals
400140.03 million134.99 millionOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.44 million40.84 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400497.17 million491.50 millionOptionable

Recent News About These Companies

Elanco (ELAN) Q1 earnings: What to expect

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arcutis Biotherapeutics stock logo

Arcutis Biotherapeutics NASDAQ:ARQT

$23.53 +0.11 (+0.47%)
As of 10:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arrowhead Pharmaceuticals stock logo

Arrowhead Pharmaceuticals NASDAQ:ARWR

$76.86 +1.93 (+2.58%)
As of 10:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$226.15 +3.09 (+1.39%)
As of 10:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$24.96 +1.97 (+8.58%)
As of 10:54 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.